Survival comparison between malignant lymphoma HIV+ versus HIV- in the post HAART era: INEN 2005-2011

• Published in: Journal of clinical oncology Vol. 30; no. 15_suppl; p. e18524
• Main Authors: Cuéllar Ponce de león, Luis Ernesto, Miranda Rosales, Luis Miguel, Samanez Figari, César, Vallejos Sologuren, Carlos
• Format: Journal Article
• Language: English
• Published: 20.05.2012
• ISSN: 0732-183X; 1527-7755
• DOI: 10.1200/jco.2012.30.15_suppl.e18524

Abstract only e18524 Background: The incidence of non-Hodgkin lymphoma in HIV patients (ARLs) is higher than in general population. In the HAART era AIDS-related lymphoma (ARL) are more frequent in patients with advanced age, delayed diagnosis, non adherent HAART, multiresistant strains of HIV. The aim of this study is to compare the clinical characteristic, prognosis factors and survival of malignant lymphomas HIV( +) vs HIV(-) at the Instituto Nacional de Enfermedades Neoplásicas. Methods: Study retrospective, individually matched, case-controlled study according to HIV serologic status (positive vs negative) for patiens newly diagnosed of non-Hodgkin lymphoma between 2005 and 2011. Results: We included 51 cases HIV (+) and 102 controls HIV (-) (Table). On diagnosis, anemia (Hemoglobin < 110 g/L) and opportunistic infections (OI) were statiscal more frequent (p<0.05) in ARL. The overall response to chemotherapy (ORC) was 76.4% (cases) and 89.2% (controls) (p<0.05). In multivariate analysis ECOG ≥ 2, OI and no response to chemotherapy increase mortality risk in ARL (p<0.05). ARL had lower 6-year Disease Free Survival (DFS) (16.0 vs 25 months) (p>0.05) and lower 6- year Overall survival (OS) (37.9 vs 49.7 months (controls) (p<0.001) than HIV (-) patients. Conclusions: In multivariate analysis ECOG ≥ 2, OI and no response to chemotherapy were adverse prognostic factors for OS in ARL. ORC is lower in ARL, though similar DFS of patients with malignant lymphoma HIV(+) vs HIV(-). [Table: see text]